General Information |
| Summary |
To determine the maximum tolerated dose (MTD) of FT538 monotherapy when administered via intraperitoneal (IP) catheter and in combination with intravenous (IV) enoblituzumab in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2023-04-28 |
| End date (estimated) |
2028-09-30 |
| Clinical feature |
| Label |
ovarian cancer |
| Link |
http://purl.obolibrary.org/obo/DOID_2394 |
| Description |
A female reproductive organ cancer that is located_in the ovary.; Xref MGI.
OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT05708924 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05708924 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT05708924 |
| Public contact |
| Email |
gelle005@umn.edu |
| Public email |
gelle005@umn.edu |
| First name |
Melissa |
| Last name |
Geller |
| Phone |
+1 612 676-4200 |
| Country |
|
| Address freetext |
Masonic Cancer Center - University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455 |
|
| Sponsors |
Masonic Cancer Center, University of Minnesota
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Suspended |
| Comment recruitment status |
Product withdrawn from clinical development |
| Estimated number of participants |
33 |
